A Phase 2 Study of Enasidenib in IDH2-Mutant Angioimmunoblastic T-Cell Lymphoma
This study is testing a new way to treat a rare type of immune system cancer called AITL. Researchers want to see if a medication called enasidenib, either alone or with another drug called rituximab, can safely stop the growth of cancer cells that have a specific genetic marker.
This study is for adults 18 and older who have been diagnosed with AITL that has an IDH2 genetic mutation. You may be eligible if your cancer has come back or continued to grow after trying at least one standard treatment.
Participants will receive the study medication and undergo regular check-ups, including blood tests, to ensure the treatment is safe and working correctly. You will need to be able to manage your daily activities and follow safety protocols regarding other medications and birth control.
The study is currently recruiting patients at locations in Boston, Massachusetts, and Basking Ridge, New Jersey. Please speak with your doctor to see if one of these centers is the right fit for your care.
- 1Tests a targeted therapy for a specific type of T-cell lymphoma.
- 2Requires a confirmed IDH2 genetic mutation to participate.
- 3The goal is to provide a new treatment option for patients whose cancer did not respond to standard care.
No related links yet
Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.
Suggest a linkThis summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.